DC Funds’s TScan Therapeutics TCRX Stock Holding History

DC Funds’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$630K	Hold	630,000	–	–	42.4%	1
2025 Q4	$630K	Hold	630,000	–	–	43.36%	1
2025 Q3	$1.15M	Hold	630,000	–	–	36.87%	2
2025 Q2	$914K	Hold	630,000	–	–	42.43%	1
2025 Q1	$869K	Hold	630,000	–	–	42.07%	1
2024 Q4	$1.92M	Hold	630,000	–	–	53.75%	1
2024 Q3	$3.14M	Hold	630,000	–	–	60.91%	1
2024 Q2	$3.69M	Hold	630,000	–	–	61.2%	1
2024 Q1	$5M	Hold	630,000	–	–	48.34%	1
2023 Q4	$3.67M	Hold	630,000	–	–	44.16%	1
2023 Q3	$1.61M	Hold	630,000	–	–	33.2%	2
2023 Q2	$1.57M	Hold	630,000	–	–	33.55%	2
2023 Q1	$1.32M	Hold	630,000	–	–	30.82%	3
2022 Q4	$977K	Hold	630,000	–	–	26.44%	3
2022 Q3	$1.92M	Hold	630,000	–	–	28.97%	3
2022 Q2	$1.98M	Hold	630,000	–	–	27.33%	3
2022 Q1	$1.76M	Hold	630,000	–	–	22.92%	3
2021 Q4	$2.83M	Hold	630,000	–	–	16.79%	3
2021 Q3	$5.25M	Buy	+630,000	New	+$5.84M	20.63%	3

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

DC Funds's TCRX Position: Q1 2026 in Review

DC Funds held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 630,000 shares worth $630K. The position accounts for 42.4% of the portfolio, ranked #1.

DC Funds first reported a position in TCRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $5.25M in Q3 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

DC Funds held 630,000 shares of TScan Therapeutics worth $630K as of Q1 2026.
DC Funds left its TScan Therapeutics share count unchanged in Q1 2026.
TScan Therapeutics made up 42.4% of DC Funds's portfolio in Q1 2026, its #1 holding.
DC Funds first reported a position in TScan Therapeutics in Q3 2021 and has held it in 19 quarters since.
DC Funds's TScan Therapeutics position peaked at $5.25M in Q3 2021.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on DC Funds's 13F filing for Q1 2026, filed 14 May 2026.